



NCCTG

NORTH CENTRAL CANCER TREATMENT GROUP

Date: March 26, 2010

To: NCCTG Primary CRAs, Primary PIs

From: Linda S. Long
Research Protocol Specialist III

Re: **N0745, Phase I/II Randomized Trial of Sorafenib and Bevacizumab as First-Line Therapy in Patients with Locally Advanced or Metastatic Hepatocellular Carcinoma**

The Fax Supply Order Form has been updated to reflect Biospecimen Accessioning Processing rather than Mayo Medical Laboratory

If you have any questions concerning this communication, please contact me at 507/266-3853.